Description General description Extremely potent and cell-permeable inhibitor of cGMP-inhibited phosphodiesterase (IC50 = 300 pM) and platelet aggregation in vitro. Potentiates adenosine-stimulated cAMP accumulation. Packaging 10 mg in Plastic ampoule Biochem/physiol Actions Cell permeable: yes Primary Target cGMP-inhibited phosphodiesterase Product does not compete with ATP. Reversible: no Target IC50: 300 pM against cGMP-inhibited phosphodiesterase Warning Toxicity: Standard Handling (A) Reconstitution Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C. Other Notes Spina, D., et al. 1998. Life Sci. 62, 953. Pillai, R., et al. 1994. J. Biol. Chem.269, 30676. Tang, K.M., et al. 1994. Eur. J. Pharmacol.268, 105. Whalin, M.E., et al. 1991. Mol. Pharmacol. 39, 711. Beavo, J.A., and Reifsnyder, D.H. 1990. Trends Pharmacol. Sci.11, 150. DeClerck, F., et al. 1990. Blood Coag. Fibrinol. 1, 247. Konkle, B.A., et al. 1990. J. Biol. Chem. 265, 21867. Ruppert, D., and Weithmann, K.U. 1982. Life Sci.31, 2037.